Biogen Inc's shock decision this week to bring its experimental Alzheimer's drug back from the scrap heap was born out of “top secret" meetings, non-disclosure agreements and six months of hashing over trial data with scientists, regulators and statisticians, researchers told Reuters.
from Reuters: Health News https://ift.tt/2BJSumk
No comments:
Post a Comment